Nebenwirkungen · Koselugo
Koselugo 10 mg hard capsules Koselugo 25 mg hard capsules · Abschnitt 4.8 · PDF-Seite 9
HOS-145445 · Präparat HOS-099352
The median total duration of selumetinib treatment in NF1-PN Paediatric Pool was 27 months (range: < 1– 97 months), 57% of patients were exposed to selumetinib treatment for > 24 months and 40% for > 36 months. The median total duration of selumetinib treatment in NF1-PN adult patients was about 12 months (range: < 1 – 32 months). Of these patients 50.4% of patients were exposed to selumetinib treatment for < 12 months and remaining 49.6% patients were exposed to selumetinib for > 12 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T11:39:00Z · SHA-256 a60a44b68868ce8319831dcd6488fab0fc72cf8efb09ef2ef5822453e45d0860 · Passage 6c42c05667c26ca6c917f85a094c360a26fe64527a7f3178809204bb8763c664 · Zeichen 941–1437 im Abschnitt